2.2. EphA2- and HDAC-Targeted Combination Therapy Results in Enhanced DNA Damage, Increased Apoptosis, and Decreased Clonogenic Survival in Endometrial Cancer Cells. The gene discussed is HDAC9; the disease is endometrial cancer.